Expert Q&A – Page 2 – media

【EXPERT Q&A】If there are no inquiries for a silver member product one month after its launch, what issues should be checked first?

Drugdu.com expert’s response: Suppliers tend to get extremely anxious when their Silver Member products have been online for a month without receiving any inquiries. This reaction is completely understandable. Enterprises sign up for membership, upload products, and wait for overseas buyers to reach out. After a month with no inquiries, it is easy for them to assume the platform is ineffective or their products have no market demand. However, from the perspective of platform operation, the lack of inquiries in the first month should not be judged solely by the result, nor can it be simply concluded that “there are no buyers”. Especially for B2B products such as pharmaceuticals, medical devices, APIs, excipients and consumables, there is an inherent screening process before buyers officially send an inquiry: from searching, browsing, comparing suppliers to making the final decision. Whether the products can be seen, matched by search algorithms, understood and trusted ...
- Source: drugdu
- 127
- October 16, 2026
【EXPERT Q&A】Why didn’t the buyer contact us again after we got back?

Drugdu.com expert’s response: Many pharmaceutical and medical device enterprises have encountered such a situation when attending exhibitions. They had a great conversation with buyers on site: the buyers listened carefully to the product introduction, asked about specifications, prices, certificates and export experience, and even exchanged business cards or added contact information. At that moment, suppliers would feel that this client is highly promising. However, after the exhibition ends, they have sent the documents and followed up via emails, but the buyers remain unresponsive. This scenario is far from rare, and it cannot be simply interpreted as “the client has no interest” or “the on-site communication was just polite small talk”. In most cases, the on-site conversation at the exhibition is only the first step for buyers to screen suppliers. When attending the exhibition, a buyer may visit dozens of booths in one day, encountering a large number of suppliers offering ...
- Source: drugdu
- 158
- October 14, 2026
【EXPERT Q&A】How to efficiently sort out medical device regulations and corresponding standards?

Drugdu.com expert’s response: When sorting out medical device regulations and standards, the most common mistake is to start reading directly from the regulatory documents themselves. For example, you may immediately dive into MDR, IVDR, FDA Guidance, NMPA announcements, and ISO standard lists. The more materials you read, the more confused you become, and in the end, you cannot figure out exactly what preparation path a specific product should follow. A more efficient approach is to place regulations and standards back into the product scenario first. That is, you need to clarify in advance: which category of product you are sorting out, which market it is intended to enter, what risk class the product belongs to, what documents are required before market launch, and what responsibilities need to be assumed after market launch. Medical device regulations do not exist in isolation, and they must ultimately be applied to a specific product. ...
- Source: drugdu
- 182
- October 12, 2026
【EXPERT Q&A】What certifications are required for the export of food additives to the United States, France, Germany, Japan and South Korea?

Drugdu.com expert’s response: When exporting food additives to the United States, France, Germany, Japan and South Korea, it cannot be simply understood as “getting one single certification to clear customs”. These markets pay more attention to whether the additive is permitted for use in local food, which food categories it can be added to, its maximum usage limit, and whether its quality specifications and label documents meet the local requirements. In other words, exporting food additives is not only about “having a certificate”, but about ensuring that the product itself is legally compliant, its intended use is approved, and the importer can complete the local declaration smoothly. The United States: Focus on FDA compliance and import requirements When exporting to the US, suppliers often claim “we have FDA certification”. But for food additives, obtaining a single FDA certificate does not mean the product can be sold freely. In the US, ...
- Source: drugdu
- 177
- October 9, 2026
【EXPERT Q&A】When an overseas buyer brings up exclusive agency right right at the start of communication, should the supplier immediately proceed with the discussion?

Drugdu.com expert’s response: When doing foreign trade in pharmaceuticals and medical devices, some inquiries may seem very appealing at first glance. The buyer hasn’t asked many detailed product questions, and hasn’t even clarified samples, prices or documents, but they will immediately put forward a request: “Can we be your exclusive distributor?” or “We want to be your exclusive agent in our market.” For suppliers, this type of information can easily arouse expectations. Compared with ordinary price inquiries, exclusive agency sounds more like long-term cooperation, and more like the channel resources that enterprises truly want when expanding overseas. Especially for enterprises that are developing overseas markets, they are already eager to find local agents, distributors or long-term partners. When they see buyers taking the initiative to propose exclusive agency, they will naturally list this lead as a top priority. However, bringing up exclusive agency right at the very beginning does not ...
- Source: drugdu
- 188
- October 7, 2026
【EXPERT Q&A】What are the trends in the medical consumables industry?

Drugdu.com expert’s response: The medical consumables industry is still growing overall, but its growth logic is no longer as simple as “large hospital consumption and fast product turnover”. For those engaged in pharmaceutical and medical device foreign trade and B2B platform operations, what deserves more attention is that while demand remains stable, buyers are raising their requirements for supply stability, compliance documentation, product segmentation and price control. 1. Basic demand remains stable: consumables are “high-frequency rigid necessities” Medical consumables cover a wide range of categories, including gloves, syringes, infusion supplies, catheters, dressings, gauze, surgical packs, non-woven fabric products, disinfection and sterilization supplies, testing consumables, respiratory consumables, incontinence care products, and more. Multiple market reports have identified infection control, chronic disease management, increasing surgical volumes, and the expansion of hospital and home care scenarios as the main growth drivers ^[Grand View Research]^. These products are characterized by high repurchase frequencies, with ...
- Source: drugdu
- 175
- October 5, 2026
【EXPERT Q&A】What are the principle of action and advantages of peptide-conjugated radionuclide drugs (PRC)?

Drugdu.com expert’s response: Peptide-radionuclide conjugates, in common contexts, are often categorized under PRRT (Peptide Receptor Radionuclide Therapy) or radiopharmaceutical conjugates. Its core concept can be summed up in one sentence: the peptide is responsible for “targeting the site”, while the radionuclide takes charge of “killing tumor cells”. This type of drug usually consists of several parts: a peptide that can recognize tumor-associated receptors, a linker/chelation structure, and a radionuclide for diagnosis or therapy. The peptide segment binds to specific receptors highly expressed on the surface of tumor cells, such as the somatostatin receptors commonly seen in neuroendocrine tumors. After binding, the receptor-peptide complex can be internalized by the cell, and the radionuclide subsequently releases radiation near or inside the tumor cell, causing DNA damage to inhibit or kill the tumor cell. PRRT precisely uses radiolabeled peptides to selectively target tumor cells that express the corresponding receptors, delivering therapeutic radiation to ...
- Source: drugdu
- 220
- October 2, 2026
【EXPERT Q&A】The buyer has started to ask about the annual purchase volume and long-term pricing. At which stage has this inquiry progressed?

Drugdu.com expert’s response: In pharmaceutical foreign trade inquiries, many communications start off very lightly. Buyers first ask if the product is available, then review the COA, specifications, and price, and sometimes request samples. At this stage, suppliers are mostly confirming product compatibility, while buyers are still screening options. However, when the conversation progresses to the point where buyers start asking about annual purchase volumes, long-term pricing, and stable supply capabilities, the situation changes. For example, if a buyer begins to inquire about how much goods they will need in a year, whether quarterly deliveries are possible, and if prices can be recalculated for long-term cooperation, such questions usually indicate that they are no longer just considering “whether they can make a single purchase” — they are assessing whether the supplier can be included in their long-term cooperation network. Of course, this does not mean an order will be placed immediately. ...
- Source: drugdu
- 219
- September 30, 2026
【EXPERT Q&A】The buyer said that the sample test has passed. How can the project be pushed to a trial order next?

Drugdu.com expert’s response: In pharmaceutical foreign trade, after sending out samples, the sentence that every salesperson most looks forward to seeing is probably: “Sample passed our test.” However, upon receiving this message, some sales representatives do not know how to follow up properly. They simply reply: “Great, looking forward to your order.” And then start waiting. Several days pass with no order from the client; a week later, they send another message: “Any update?” The client replies: “We are still discussing internally.” Gradually, the entire project grinds to a halt. A sample passing the test is certainly good news, but there is usually a noticeable gap between “qualified sample” and “formal procurement”. At this stage, what suppliers need to confirm is no longer whether the product is usable, but how the client plans to make the purchase. Confirm the purchase quantity and timeline right after sample approval The sample phase is meant to ...
- Source: drugdu
- 148
- September 28, 2026
【EXPERT Q&A】When a buyer makes an inquiry and only leaves the product name and country, which questions should be asked in the first round?

Drugdu.com expert’s response: In pharmaceutical foreign trade, it is very common to receive extremely short inquiries. For example: “Need Vitamin D3, Pakistan.” or “Looking for disposable syringe, UAE.” Sometimes buyers only leave the product name, country and email address, with no other information provided. There are no specifications, no quantity, no intended use, and no explanation of whether they are importers, distributors or end purchasers. Such inquiries cannot be directly judged as invalid. Some buyers are just testing whether the supplier will respond, some are sourcing goods for their end clients, and some have not sorted out their complete requirements yet. The focus of your first reply is not to quote immediately, nor to send all product catalogs and certificates at once. Instead, you should first ask for several most critical pieces of information. Confirm the specific specification or model first The product name alone provided by the buyer is ...
- Source: drugdu
- 137
- September 25, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.